Product image of Midiana (Drospirenone, Ethinylestradiol) supplied by GNH India

Midiana

Active Ingredient:
Drospirenone, Ethinylestradiol
Origin:
EU

Midiana (Drospirenone, Ethinylestradiol)

Drospirenone, the active ingredient in Midiana, is a combined oral contraceptive presented as a unknown/oral tablet for oral use. It treats prevention of pregnancy and menstrual cycle regulation in women of reproductive age.

GNH India supplies Midiana as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Midiana, a combined oral contraceptive, is used to manage hormonal contraception and menstrual regulation.

  • Prevention of pregnancy: provides reliable contraceptive protection by suppressing ovulation.
  • Menstrual cycle regulation: helps achieve more predictable bleeding patterns.
  • Management of ovulatory disorders: inhibits luteinizing hormone and follicle‑stimulating hormone release to prevent ovulation.

How It Works

  • Drospirenone and ethinylestradiol act together to inhibit the hypothalamic‑pituitary‑ovarian axis, suppressing the surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) required for ovulation. The estrogen component stabilises the endometrial lining, while the progestin component thickens cervical mucus and further alters the endometrium, creating an environment unsuitable for fertilisation and implantation.

Side Effects

Midiana may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: discomfort or swelling of breast tissue.
  • Headache: occasional tension‑type headache.
  • Spotting or breakthrough bleeding: irregular light bleeding between periods.
  • Mood changes: irritability or mild mood swings.
  • Weight gain: modest increase in body weight.

Serious or Rare Side Effects

  • Deep vein thrombosis: formation of blood clots in deep veins.
  • Pulmonary embolism: clot migration to lung vessels.
  • Stroke or transient ischemic attack: neurological events due to vascular blockage.
  • Myocardial infarction: heart attack risk, especially in high‑risk groups.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Liver dysfunction: abnormal liver enzyme elevations or jaundice.

Precautions & Warnings

Before prescribing Midiana, clinicians should evaluate patient history and risk factors.

  • Pregnancy contraindication: do not use in women who are or may become pregnant.
  • Smoking restriction: avoid in women over 35 who smoke more than 15 cigarettes per day.
  • Thromboembolic history: contraindicated in patients with prior clotting disorders.
  • Liver disease: use with caution in hepatic impairment.
  • Hypertension: monitor blood pressure regularly.
  • Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Midiana can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Anticoagulants (e.g., warfarin): may reduce anticoagulant effect.
  • Enzyme‑inducing antiepileptics (e.g., phenytoin, carbamazepine): lower hormone levels, decreasing contraceptive reliability.
  • Rifampin or St. John’s wort: strong inducers that diminish oral contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

  • Certain antifungals (e.g., ketoconazole): may increase hormone concentrations.
  • SSRIs (e.g., fluoxetine): can heighten bleeding risk.
  • Diuretics (e.g., spironolactone): may increase serum potassium.
  • NSAIDs: may elevate blood pressure, requiring monitoring.

Frequently Asked Questions

Midiana is a combined oral contraceptive that provides reliable prevention of pregnancy and helps regulate the menstrual cycle. It works by suppressing ovulation and modifying cervical mucus and the endometrial lining, making it unsuitable for fertilisation and implantation.

The drospirenone/ethinylestradiol combination blocks the release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH) from the pituitary gland, preventing ovulation. Drospirenone also thickens cervical mucus and alters the uterine lining, while ethinylestradiol stabilises the endometrium, together creating multiple barriers to conception.

The dosage regimen for Midiana is determined by the prescribing healthcare professional. Typically, it is taken as a daily oral tablet following the specific cycle schedule indicated on the prescription label. Patients should follow the prescriber’s instructions exactly.

Midiana is contraindicated in pregnancy and must not be used by women who are pregnant or may become pregnant. It is also not recommended for breastfeeding mothers because hormonal contraceptives can pass into breast milk and may affect the infant. Alternative methods should be discussed with a healthcare provider.

To order Midiana, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Midiana contains drospirenone, a progestin with anti‑androgenic and mild diuretic properties, which may offer benefits such as reduced water retention and improved acne compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, but individual tolerability and side‑effect profiles can differ.

Midiana tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Keep the medication away from moisture, heat and direct sunlight to maintain stability and potency throughout its shelf life.

Midiana is taken orally, usually once daily at the same time each day. The tablets are swallowed with water and can be taken with or without food. Patients should follow the prescribed cycle, typically 21 active tablets followed by a hormone‑free interval, unless directed otherwise by their clinician.

The most serious risks include venous thromboembolism (deep‑vein thrombosis, pulmonary embolism), arterial events such as stroke or myocardial infarction, and severe allergic reactions. Women with a history of clotting disorders, smoking over 15 cigarettes per day, or certain cardiovascular conditions should be evaluated carefully before use.

Midiana should not be used by women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or who are smokers over the age of 35. It is also contraindicated in individuals with known hypersensitivity to drospirenone, ethinylestradiol or any excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Drospirenone, Ethinylestradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT